Alvotech and DKSH, a healthcare provider across 36 emerging countries in South-East Asia, have expanded their partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas.   “We have been delighted to work with DKSH since our initial partnership began earlier this year,” said Mark Levick, chief executive officer, Alvotech. “The partnership is designed to accelerate improved pati...